COVID-19 VACCINATION AND NATURAL INFECTION’S RESPONSES IN A COHORT of PATIENTS WITH INBORN ERROR of IMMUNITY FROM ARGENTINA

ERRA, LORENZO; URIARTE, IGNACIO; BEDROZNIK, LILIANA; ALMEJÚN MARÍA BELÉN

Congreso; 20th International Meeting of the European Society for Immunodeficiency 2020; 2022

Background and Aims: Patients with Inborn Errors of Immunity (IEI) in Argentina were encouraged to receive the authorized Sputnik, AstraZeneca, Sinopharm, Moderna and Pfizer vaccines. Most data on available vaccines derive from trials conducted on healthy individuals. Our aim was to evaluate the safety and immunogenicity of the different vaccines in IEI patients in Argentina.Methods: The study cohort included adults and pediatric IEI patients (n=118) and age-matched healthy-controls (HC) (n=37). Samples were collected before, 28+/-3 days after the first and the second doses (T2) of the vaccine. B-cellresponse was evaluated by measuring IgG anti-Spike(S)/RBD and anti-nucleocapsid(N) antibodies by ELISA.Neutralization antibodies were also assessed at T2 with an alpha-S protein-expressing pseudo-virus assay. The T-cellresponse was analyzed by IFN-γ secretion on S or N-stimulated PBMC by ELISPOT and the frequency of S-specificcirculating T follicular-helper cells (TFH) by flow cytometry.Results: No moderate/severe vaccine-associated adverse events were observed. Regarding the antibody response,anti-S/RBD titers showed significant differences between IEI patients pediatric and adults with the age-matched HCcohort (p